These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24589363)

  • 21. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
    Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
    PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
    Claas GJ; Jülg B; Goebel FD; Bogner J
    Eur J Med Res; 2007 Feb; 12(2):54-60. PubMed ID: 17369118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
    Chi BH; Mwango A; Giganti M; Mulenga LB; Tambatamba-Chapula B; Reid SE; Bolton-Moore C; Chintu N; Mulenga PL; Stringer EM; Sheneberger R; Mwaba P; Stringer JS
    J Acquir Immune Defic Syndr; 2010 May; 54(1):63-70. PubMed ID: 20009765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
    Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
    van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of ART in resource-limited countries.
    Loubiere S; Meiners C; Sloan C; Freedberg KA; Yazdanpanah Y
    Curr Opin HIV AIDS; 2010 May; 5(3):225-31. PubMed ID: 20539078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.
    Havens PL; Hazra R
    Pediatr Infect Dis J; 2015 Apr; 34(4):406-8. PubMed ID: 25599283
    [No Abstract]   [Full Text] [Related]  

  • 33. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
    Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
    Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.
    Bygrave H; Ford N; van Cutsem G; Hilderbrand K; Jouquet G; Goemaere E; Vlahakis N; Triviño L; Makakole L; Kranzer K
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e75-8. PubMed ID: 21164354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Hoffmann CJ; Wood R; Boulle A; Giddy J; Prozesky H; Vinikoor M; Mwanza MW; Wandeler G; Davies MA; Fox MP
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):413-416. PubMed ID: 29206723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
    Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
    PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.